X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (108) 108
index medicus (103) 103
male (80) 80
oncology (79) 79
middle aged (78) 78
female (75) 75
aged (64) 64
cancer (61) 61
adult (51) 51
care and treatment (29) 29
chemotherapy (27) 27
treatment outcome (26) 26
antineoplastic agents - therapeutic use (22) 22
neoplasms - drug therapy (21) 21
therapy (21) 21
tumors (21) 21
carcinoma, renal cell - drug therapy (19) 19
patients (19) 19
antineoplastic agents - adverse effects (18) 18
aged, 80 and over (17) 17
kidney neoplasms - drug therapy (17) 17
metastasis (17) 17
research (17) 17
carcinoma (16) 16
head and neck cancer (16) 16
disease-free survival (15) 15
medicine & public health (15) 15
pharmacology & pharmacy (15) 15
antineoplastic agents (13) 13
cancer patients (13) 13
kidney neoplasms - pathology (13) 13
head and neck neoplasms - drug therapy (12) 12
radiotherapy (12) 12
squamous-cell carcinoma (12) 12
trial (12) 12
antimitotic agents (11) 11
antineoplastic agents - administration & dosage (11) 11
head and neck neoplasms - pathology (11) 11
original (11) 11
sunitinib (11) 11
surgery (11) 11
young adult (11) 11
analysis (10) 10
chemoradiotherapy (10) 10
clinical trials (10) 10
drug administration schedule (10) 10
otorhinolaryngology (10) 10
retrospective studies (10) 10
survival (10) 10
toxicity (10) 10
tyrosine kinase inhibitor (10) 10
antineoplastic agents - pharmacokinetics (9) 9
antineoplastic combined chemotherapy protocols - adverse effects (9) 9
antineoplastic combined chemotherapy protocols - therapeutic use (9) 9
cisplatin (9) 9
head and neck neoplasms - therapy (9) 9
hematology, oncology and palliative medicine (9) 9
neoplasm metastasis (9) 9
oncology, experimental (9) 9
pharmacokinetics (9) 9
renal cell carcinoma (9) 9
renal-cell carcinoma (9) 9
time factors (9) 9
angiogenesis (8) 8
animals (8) 8
antineoplastic combined chemotherapy protocols - administration & dosage (8) 8
bevacizumab (8) 8
biomarkers (8) 8
cancer therapies (8) 8
carcinoma, renal cell - pathology (8) 8
dose-response relationship, drug (8) 8
expression (8) 8
head & neck cancer (8) 8
head and neck neoplasms - mortality (8) 8
indoles - adverse effects (8) 8
maximum tolerated dose (8) 8
neoplasms - metabolism (8) 8
niacinamide - analogs & derivatives (8) 8
protein kinase inhibitors - adverse effects (8) 8
pyrroles - adverse effects (8) 8
angiogenesis inhibitors (7) 7
breast cancer (7) 7
carcinoma, renal cell - secondary (7) 7
carcinoma, squamous cell - drug therapy (7) 7
drug therapy (7) 7
fatigue (7) 7
immunotherapy (7) 7
kaplan-meier estimate (7) 7
management (7) 7
medical research (7) 7
metastases (7) 7
prognosis (7) 7
protein kinase inhibitors - therapeutic use (7) 7
quality of life (7) 7
radiation-therapy (7) 7
risk factors (7) 7
safety (7) 7
sorafenib (7) 7
adolescent (6) 6
carcinoma, squamous cell - pathology (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


BRITISH JOURNAL OF CANCER, ISSN 0007-0920, 07/2019, Volume 121, Issue 1, pp. 34 - 36
Advances in molecular tumour diagnostics and the number of targeted therapies increase rapidly. Molecular tumour boards (MTBs) are designated to interpret... 
UNIVERSITY-OF-CALIFORNIA | IMPACT | ONCOLOGY | MEDICINE | Medical research | Cost assessments | Diagnostic tests | Quality control | Clinical trials | Oncology | Knowledge management | Medical diagnosis | Patients | Tumors | Cancer
Journal Article
The Lancet Oncology, ISSN 1470-2045, 04/2019, Volume 20, Issue 4, pp. e200 - e207
Renal or hepatic impairment is a common comorbidity for patients with cancer either because of the disease itself, toxicity of previous anticancer treatments,... 
DOSAGE ADJUSTMENT | ADVANCED SOLID TUMORS | CANCER-PATIENTS | HIGH-FLUX | PHARMACOKINETICS | ONCOLOGY | LIVER-FUNCTION | VARYING DEGREES | OPEN-LABEL | DYSFUNCTION | PHASE-I | Antimitotic agents | Drugstores | Care and treatment | Antineoplastic agents | Comorbidity | Pharmacy
Journal Article
Journal of Nuclear Medicine, ISSN 0161-5505, 04/2013, Volume 54, Issue 4, pp. 532 - 540
This prospective study used sequential PET with the proliferation tracer 3'-deoxy-3'-F-18-fluorothymidine (F-18-FLT) to monitor the early response to treatment... 
TUMOR PROLIFERATION | METAANALYSIS | head and neck cancer | RECONSTRUCTION | F-18-fluorothymidine PET | CHEMOTHERAPY | RADIATION-THERAPY | POSITRON-EMISSION-TOMOGRAPHY | CANCER-PATIENTS | ONCOLOGY | LOCALLY ADVANCED HEAD | early response monitoring | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Journal Article
Supportive Care in Cancer, ISSN 0941-4355, 4/2018, Volume 26, Issue 4, pp. 1233 - 1242
Journal Article
The Lancet Oncology, ISSN 1470-2045, 06/2019, Volume 20, Issue 6, pp. e290 - e290
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 11/2019, Volume 106, Issue 5, pp. 1076 - 1082
Pazopanib is taken fasted in a fixed oral daily dose of 800 mg. We hypothesized that ingesting pazopanib with food may improve patients’ comfort and reduce... 
Journal Article
Supportive Care in Cancer, ISSN 0941-4355, 11/2019, Volume 27, Issue 11, pp. 4145 - 4154
Knowledge of caregivers’ burden and fatigue before and after patients’ treatment for locally advanced head and neck cancer is scarce. Therefore, we aimed to... 
Pain Medicine | Nursing | Rehabilitation Medicine | Medicine & Public Health | Nursing Research | LAHNC | Caregiver | Oncology | Fatigue | Burden | Chemoradiotherapy | Head and neck cancer | Care and treatment | Research | Oncology, Experimental | Cancer | Original
Journal Article
Oncotarget, ISSN 1949-2553, 03/2019, Volume 10, Issue 19, p. 1850
and are the most frequently mutated mitogen-activated protein kinase (MAPK) genes in melanoma. Binimetinib is a highly selective MAPK kinase (MEK) 1/2... 
Journal Article
Journal Article
International journal of cancer, ISSN 0020-7136, 05/2016, Volume 138, Issue 10, p. 2312–2321
Mammalian target of rapamycin inhibitors (mTORi) have clinically significant activity against various malignancies, such as renal cell carcinoma and breast... 
Journal Article
Molecular Pharmaceutics, ISSN 1543-8384, 06/2017, Volume 14, Issue 6, p. 2147
The combination of methotrexate with epidermal growth factor receptor (EGFR) recombinant antibody, cetuximab, is currently being investigated in treatment of... 
Journal Article
Head and Neck, ISSN 1043-3074, 01/2017, Volume 39, Issue 1, p. 140
Background: There is an ongoing debate about the value of (neo-)adjuvant chemotherapy in high- and intermediate-grade osteosarcoma of the head and neck.... 
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.